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detected by strain analysis using both echocardiography and CMRI. CMRI
is feasible and safe in patients with MitraClips.
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The impact of socioeconomic status (SES) on heart failure (HF)
treatment, hospitalization andmortality has been previously studied
[1]. Several challenges impose on deprived groups once HF is
established: healthcare access, transportation costs, affordability of
drug regimens [2,3]. Clinicians' perception of these factors may also
change their threshold for prescribing therapies.
InPortugal, literacy levels arebelowtheEuropeanaverage; theaverage
income is lowwith awide ditch between the top 20% and the bottom20%
of the population. Portugal´s health system is based on the delivery of
care by state organizations and intends to be universal and equal.
We investigated if SES inﬂuences prognosis after an acute episode
of HF and to determine if prognostic-modifying therapy is delivered
equitably.
During 21 months of a registry of all patients admitted to our
Department due to acute HF, 616 patients were discharged alive. Patients
provided informed consent. The study protocol conforms to the ethical
principles of the declaration of Helsinki.
Information on socioeconomic data was obtained from the patients
or their next-of-kin. A socioeconomic deprivation index (SEDI) was
created using the following formula: SEDI = income + educational
level + living alone, where income= 1 if bminimum wage or 0
if ≥minimum wage; educational level =1 or =0 if ≤4 years or
N4 years in school, respectively; and living alone =1. The SEDI could
thus assume values between 0 and 3, with higher scores indicating lower
SES. For prognostic analysis patients were categorized in 2 groups: 0
versus 1 to 3 points in SEDI. Information on socioeconomic variables was
obtained in 600 patients. Patients were followed for 6 months.
The endpoints under study were prescription of angiotensin
converting enzyme inhibitors (ACEi) or angiotensin II receptor
blockers (ARB) and beta blockers (BB) at hospital discharge, and 6-
month all-cause mortality and all-cause hospital readmissions.
A multivariate logistic regression analysis was used to determine the
inﬂuence of socioeconomic variables on the prescription of prognostic-
modifying therapy at hospital discharge. Variables expected to inﬂuence
the prescription - diabetesmellitus, arterial hypertension, coronary heart
disease, left ventricular systolic dysfunction and age - were included in
the model as covariates.
We used Cox regression analysis to quantify the prognostic impact of
the SES as determined by the SEDI. An age-, sex- and admission BNP-
adjusted analysis was performed.
Patient's characteristics according to educational level and income are
summarized in Table 1. Patients with lower income were less often
medicated with ACEi and/or ARB at discharge. This association of lower
income with less intention to treat with an ACEi and/or ARB was mainly
explained byother variables expected to inﬂuence its prescription namely
arterial hypertension; left ventricular systolic dysfunction and age. The
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adjusted OR for ACEi/ARB prescription was 0.67 (0.43–1.04), p = 0.07.
The prescription of BB was not associated with socioeconomic variables
(Table 2).
During the 6-month follow-up 122 (20.3%) patients died and
237 (39.5%) were readmitted. Patients' SEDI distribution was as
follows: no adverse factor: 69 (11.5%) patients; 1 adverse factor 172
(28.7%), 2 adverse factors 302 (50.3%) and all 3 adverse factors: 57
(9.5%) (Fig. 1).
Patientswith at least one adverse factor had aHRof all-cause hospital
readmission up to 6-months of 2.01 (95% CI: 1.21–3.34, p value =0.007);
the HR of all-cause death was 1.48 (95% CI: 0.77–2.82,
p value = 0.24). Patients with SEDI ≥1 had an age-, sex- and
admission BNP-adjusted HR of hospital readmission of 1.91 (95% CI:
1.14–3.19; p value = 0.01).
In a large group of consecutive HF patients, we found that
deprived patients had higher morbidity but non-different mortality.
Patients with socio-economic deprivation had an almost double risk
of hospital readmission within 6 months. The vast majority of our
patients beneﬁted from the pharmacological therapies known to
improve outcome, although patients with low income tended to be
less treated with ACEi and/or ARB upon discharge.
Equity in health access is an international priority [4]. Preventable
inequalities are unfair and indicate distributional differences of care
delivery. There is robust evidence demonstrating outcome improvement
with pharmacological treatment in the whole spectrum of HF severity.
Only a few studies have examined the prescription of HF prognostic-
modifying therapy according to SES. In Scotland, where treatment is
charge free, ACEi and BB prescription did not vary according to SES [5].
Similar observations were made in the United States (25). Discrepant
results have been reported in Germany where BB prescription was
signiﬁcantly lower inmore deprived patients [6]. In our population there
was no interference between SES and BB prescription; a trend to lower
ACEi/ARB prescription in patients with lower income was observed but
stillwith ahigh frequencyof useof this prognosismodifyingmedications.
Several studies show that deprived patients hospitalized with HF are
at higher risk of readmission. These observations have been reported in
different developed countries. Studies from England and USA observed
higher hospital readmissions in the most deprived patients [1,2,7].
Table 1
Patient characteristics and comparison according to educational level and income.
Education Income
All patients
n = 600
≤4 years
n = 492
N4 years
n = 108
p value Below
minimum wage
n = 355
Above
minimum wage
n = 245
p value
Clinical characteristics
Male sex, n (%) 268 (44.7) 197 (40.0) 71 (65.7) b0.001 132 (37.2) 136 (55.5) b0.001
Age (years), median (IQR) 78 (71–84) 79 (72–84) 76 (64–83) 0.005 79 (72–85) 77 (68–84) 0.02
Institutionalized, n (%) 27 (4.5) 23 (4.7) 4 (3.7) 0.85 20 (5.6) 7 (2.9) 0.16
Arterial hypertension, n (%) 444 (76.6) 372 (78.3) 72 (68.6) 0.04 265 (76.6) 179 (76.5) 1.00
Diabetes mellitus, n (%) 241 (43.0) 204 (44.3) 37 (37.0) 0.22 131 (39.8) 110 (47.4) 0.09
Coronary heart disease, n (%) 244 (40.9) 193 (39.5) 51 (47.2) 0.17 134 (37.9) 110 (45.3) 0.08
LVSD, n (%) 324 (55.1) 261 (54.3) 63 (58.9) 0.45 184 (53.5) 140 (57.4) 0.40
Triggered by non-adherence to therapy, n (%) 158 (27.0) 136 (28.4) 22 (20.6) 0.13 102 (29.2) 56 (23.6) 0.16
BMI (Kg/m2), median (IQR) 25.2 (22.6–27.8) 25.1 (22.6–27.8) 25.4 (22.7–28.0) 0.68 25.1 (22.6–27.9) 25.4 (22.8–27.8) 0.57
Admission laboratory parameters
Hemoglobin (g/dL), median (IQR) 11.6 (10.4–13.3) 11.6 (10.4–13.2) 11.8 (10.1–13.7) 0.55 11.6 (10.4–13.3) 11.7 (10.4–13.2) 0.88
Creatinine (mg/L), median (IQR) 1.37 (1.10–1.82) 1.35 (1.10–1.84) 1.40–(1.10–1.79) 0.63 1.35 (1.10–1.89) 1.39 (1.12–1.74) 0.58
BNP (pg/mL), median (IQR) 1586.8 1581.0 1595.1 1533.3 1667.4
(915.0–2785.2) (884.6–2810.9) (1043.4–2589.0) 0.82 (903.1–2890.7) (955.3–2710.6) 0.80
Previous medications in use
Beta-blocker, n (%) 292 (49.1) 240 (49.2) 52 (48.6) 1.00 172 (48.7) 120 (49.6) 0.90
ACEi or ARB, n (%) 371 (62.1) 307 (62.7) 64 (59.8) 0.66 214 (60.5) 157 (64.6) 0.35
Spironolactone, n (%) 81 (13.6) 65 (13.3) 16 (15.0) 0.77 52 (14.7) 29 (12.0) 0.40
Spironolactone, n (%) 81 (13.6) 65 (13.3) 16 (15.0) 0.77 52 (14.7) 29 (12.0) 0.40
Discharge medication
Beta-blocker, n (%) 453 (75.9) 369 (75.3) 84 (78.5) 0.56 264 (74.6) 189 (77.8) 0.42
ACEi or ARB, n (%) 472 (78.9) 382 (77.8) 90 (84.1) 0.19 269 (75.8) 203 (83.5) 0.03
Spironolactone, n (%) 140 (23.5) 108 (22.0) 32 (29.9) 0.11 82 (23.2) 58 (23.9) 0.92
All-cause death, n (%) 122 (20.4) 103 (21.0) 19 (17.6) 0.51 74 (20.8) 48 (19.7) 0.80
All-cause rehospitalization or death, n (%) 277 (46.2) 234 (47.7) 43 (39.8) 0.17 174 (49.0) 103 (42.2) 0.12
ACEi: angiotensin converting enzyme inhibitor, ARB angiotensin II receptor 1 blocker, BMI: body mass index; BNP: brain natriuretic peptide; HF: heart failure, ICD: implantable
cardiodeﬁbrillator; IQR: interquartile range, LVSD: left ventricular systolic dysfunction.
Table 2
Socio-economic variables and prescription of ACE-i or ARB and beta-blockers at hospital discharge: univariate and multivariate analysis.
ACEi/ARB Beta-blocker
Crude OR
(95% CI), p value
Adjusted⁎ OR
(95% CI), p value
Crude OR
(95% CI), p value
Adjusted⁎ OR
(95% CI), p value
Income b national minimum wage 0.63 (0.42–0.95), 0.03 0.67 (0.43–1.04), 0.07 0.88 (0.60–1.29), 0.51 0.99 (0.65–1.50), 0.96
Education ≤ 4 years 0.65 (0.37–1.14), 0.13 0.69 (0.38–1.24), 0.021 0.84 (0.51–1.39), 0.50 0.90 (0.52–1.56), 0.71
Living alone 2.78 (1.40–5.51), 0.003 2.65 (1.30–5.36), 0.007 1.15 (0.68–1.92), 0.60 1.20 (0.69–2.10), 0.51
SES index ≥1 0.92 (0.72–1.18), 0.52 0.95 (0.73–1.23), 0.68 0.88 (0.48–1.62), 0.69 1.00 (0.52–1.91), 1.00
ACEi: angiotensin converting enzyme inhibitors; ARB: angiotensin II receptor blockers; OR: odds ratio; CI: conﬁdence interval.
⁎ adjusted for left ventricular systolic dysfunction, age, diabetes mellitus, arterial hypertension and coronary artery disease.
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Our results extend these observations and show that also in Portugal,
a south European nation, the more deprived HF patients are at higher
risk of hospital readmissions. These results should help programming
political and clinical strategies, aimed to improve the outcome in this
frail group of patients in order to attain the national objective of
having non-SES dependent outcomes.
In several studies, the relation between SES and mortality paralleled
that observed with hospitalization. Some European and US studies have
shown that survival was poorer among the most deprived patients.
Other observations did not ﬁnd an association between SES and
mortality in HF [8]. Our data extend this observation, suggesting that
socio-economic deprivation is currently not a major factor associated
with mortality in HF patients.
In our acute HF population deprived patients were at higher risk of
hospital readmission, however not in higher risk of mortality. Treatment
was independent of SES suggesting that medical therapy is currently
being delivered in an equitable fashion in Portugal.
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Fig. 1. Survival and hospitalization-free curves according to socioeconomic deprivation (patients with no adverse socioeconomic factor vs those with at least one socioeconomic
deprivation factor.A: All cause death and SES index.B: All cause readmission and SES.
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